CCRM accelerates the translation of scientific discovery into marketable products and new companies with specialized teams, diligence, funding and infrastructure, tied to global academic, industry and commercialization networks. CCRM has over 80 personnel and 40,000 ft2 (~3,700 m2) of space supporting new technology development, new company creation, process optimization and scale-up, and advanced manufacturing. In October 2018, CCRM will have an operational Good Manufacturing Practices (GMP) facility. Clients who work with CCRM in the Centre for Advanced Therapeutic Cell Technologies (CATCT) will be able to do process development with CCRM and then those processes will be transferred to the GMP facility to manufacture cell and gene therapy products for Phase 1 and 2 clinical trials.